Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy combined with tislelizumab for fertility-sparing treatment of cervical cancer
ChiCTR2300067495Phase 4Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in Cervical Cancer (CC), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Pathological complete response rate and 3-year disease-free survival. Started Mar 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300067495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067495.